A kit for diagnosing gastric tumors by detecting the expression level of CTRB1 protein

Through the enzyme-linked immune kit to detect the expression level of CTRB1 protein, the problem of insufficient sensitivity and specificity of existing gastric tumor diagnostic markers is solved, and high accuracy diagnosis of early gastric tumors is achieved, providing an effective clinical detection tool.

CN115728484BActive Publication Date: 2024-11-05FUDAN UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202111021364.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-09-01
Publication Date
2024-11-05
Estimated Expiration
2041-09-01

AI Technical Summary

Technical Problem

Existing gastric tumor diagnostic markers have poor sensitivity and low specificity, making it difficult to detect gastric tumors in the early stage, resulting in missing the best time during treatment.

Method used

An enzyme-linked immune kit that detects the expression level of CTRB1 protein is developed. Using CTRB1 protein and its antibodies, the concentration of CTRB1 protein in serum in patients with gastric tumors is detected by ELISA, providing a basis for diagnosing gastric tumors.

Benefits of technology

By detecting CTRB1 protein levels, the early diagnosis accuracy of gastric tumors is significantly improved, providing a diagnostic tool with high specificity and sensitivity that can effectively identify gastric tumors in clinical tests.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115728484B_ABST
    Figure CN115728484B_ABST
Patent Text Reader

Abstract

The present invention relates to the use of a kit for detecting the expression level of CTRB1 protein in the preparation of a kit for diagnosing gastric tumors, and a kit for diagnosing gastric tumors by detecting the expression level of CTRB1 protein. Compared with the prior art, the present invention discovers the upregulated protein CTRB1 in the serum of gastric tumor patients through research, and provides a basis for using a kit for detecting such protein as a kit for diagnosing gastric tumors, as well as a threshold standard for determining gastric tumors using the kit, that is, using its characteristics to establish a kit for diagnosing gastric tumors, and the kit can be used for clinical detection of gastric tumors. The results show that the CTRB1 protein is significantly more expressed in the serum of gastric tumor patients than in healthy people, so the kit for diagnosing gastric tumors by detecting the concentration of CTRB1 protein of the present invention has outstanding application value in the clinical test of diagnosing gastric tumors through peripheral blood.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine, and relates to a kit for diagnosing gastric tumors by detecting the expression level of CTRB1 protein, and particularly to the use of the kit for detecting the expression level of CTRB1 protein in the preparation of an enzyme-linked immunosorbent assay kit for differential diagnosis of gastric tumors. Background Art

[0002] Gastric cancer is the third most deadly malignant tumor in the world. According to statistics, there were 1.033 million new cases of gastric cancer and 783,000 deaths from gastric cancer in 2018. The highest incidence and mortality rates are in eastern Asia, with China being the most common.

[0003] Gastric tumors are highly heterogeneous tumors. In recent years, due to the continuous improvement of diagnostic capabilities, the increase in the detection rate of early gastric cancer, and the continuous improvement of surgical methods, the overall level of its treatment has been significantly improved. However, various treatment methods are still faced with problems such as poor sensitivity and specificity of chemotherapy drugs, and lack of effective second-line drugs. The most effective way is to detect gastric tumors in their early development process in time to avoid patients missing the best treatment time, but existing tumor markers generally have disadvantages such as poor sensitivity and low specificity.

[0004] At present, the most commonly tested serum standards for gastric tumors include CEA and CA19-9, but since their levels are elevated in many adenocarcinomas, their specificity is not high, and multiple indicators need to be combined to increase the positive rate. Therefore, finding early markers for gastric tumors is still an urgent and pressing international problem that needs to be solved. Summary of the invention

[0005] The purpose of the present invention is to provide a kit for diagnosing gastric tumors by detecting the expression level of CTRB1 protein. The present invention uses the CTRB1 protein level as a marker for screening gastric tumors, which has outstanding application value.

[0006] The purpose of the present invention can be achieved by the following technical solutions:

[0007] A kit for detecting the expression level of CTRB1 protein is used in the preparation of a kit for diagnosing gastric tumors. The kit for detecting the expression level of CTRB1 protein can be any kit as long as it can meet the requirement of being able to detect the concentration of CTRB1 protein in the system.

[0008] Preferably, the kit for detecting the expression level of CTRB1 protein is an enzyme-linked immunosorbent assay kit.

[0009] Furthermore, the kit for detecting the expression level of CTRB1 protein contains one or more of CTRB1 protein, CTRB1 protein antibody, CTRB1 protein marker, and CTRB1 protein antibody marker. The kit for detecting the expression level of CTRB1 protein can be prepared using CTRB1 protein and / or its antibody.

[0010] Furthermore, the CTRB1 protein antibody is a monoclonal antibody or a polyclonal antibody, the monoclonal antibody is an antibody obtained by culturing a hybridoma cell line in vitro or an antibody obtained from a commercial source, and the polyclonal antibody is an antibody obtained from a commercial source. The monoclonal antibody can be purchased from Santa Cruz (Cat. No. sc-398721).

[0011] Preferably, the kit for detecting the expression level of CTRB1 protein is an enzyme-linked immunosorbent assay kit with the product number EK13508 produced by Signal Antibody, and the name of the kit is Human Chymotrypsinogen B1 (CTRB1) ELISA Kit.

[0012] A kit for diagnosing gastric tumors is prepared from a kit for detecting the expression level of CTRB1 protein.

[0013] Preferably, the kit for detecting the expression level of CTRB1 protein is an enzyme-linked immunosorbent assay kit.

[0014] Furthermore, the kit for detecting the expression level of CTRB1 protein contains one or more of CTRB1 protein, CTRB1 protein antibody, CTRB1 protein marker, and CTRB1 protein antibody marker. The kit for detecting the expression level of CTRB1 protein can be prepared using CTRB1 protein and / or its antibody.

[0015] Furthermore, the CTRB1 protein antibody is a monoclonal antibody or a polyclonal antibody, the monoclonal antibody is an antibody obtained by culturing a hybridoma cell line in vitro or an antibody obtained from a commercial source, and the polyclonal antibody is an antibody obtained from a commercial source. The monoclonal antibody can be purchased from Santa Cruz (Cat. No. sc-398721).

[0016] Preferably, the kit for detecting the expression level of CTRB1 protein is an enzyme-linked immunosorbent assay kit with the product number EK13508 produced by Signal Antibody, and the name of the kit is Human Chymotrypsinogen B1 (CTRB1) ELISA Kit.

[0017] Studies have shown that secretory proteins are closely related to cell connection, metastasis, differentiation, proliferation and tumorigenesis, and are also an important source for screening tumor markers. The present invention found through screening that the extracellular secretory protein CTRB1 is significantly upregulated in the microenvironment of gastric cancer tissue, and then creatively uses the CTRB1 protein level as a marker for screening gastric tumors.

[0018] Among them, the kit for diagnosing gastric tumors can be a conventional enzyme-linked immunosorbent assay kit that can detect the expression level of CTRB1 protein, which usually includes a solid phase carrier, a marker, and a substrate that can undergo a colorimetric reaction with the marker.

[0019] There are many materials for solid phase carriers, such as polystyrene, cellulose, polyacrylamide, polyethylene, polypropylene, cross-linked dextran, glass, silicone rubber, agarose gel, etc. The solid phase carrier can be in the form of a test tube, a microplate concave hole, a small bead, a small disc, etc. The solid phase carrier is preferably a microplate concave hole made of polystyrene, which has a strong protein adsorption performance. After the antigen is adsorbed on it, it still retains the original immune activity, has a low blank value, a high transparency of the bottom of the hole, and similar performance between plates and between wells in the same plate.

[0020] The marker is an enzyme-labeled CTRB1 protein, an enzyme-labeled CTRB1 protein antibody, a biotin-labeled CTRB1 protein, or a biotin-labeled CTRB1 protein antibody. The marker can be made of CTRB1 protein or CTRB1 protein antibody. The labeling enzyme used for the marker is horseradish peroxidase, alkaline phosphatase, or biotin, preferably horseradish peroxidase.

[0021] When the marker is horseradish peroxidase, the substrate that undergoes a colorimetric reaction with the enzyme marker consists of substrate A and substrate B, wherein substrate A is hydrogen peroxide or urea peroxide, and substrate B is o-phenylenediamine (OPD), 3',3',5',5'-tetramethylbenzidine (TMB) or ABTS [2,2'-azino-di-(3-ethylbenziazobine sulfonate-6)]; when the marker is alkaline phosphatase, the substrate is 4-nitrophenol phosphate buffer; when the marker is biotin, substrate A is enzyme-labeled avidin, and substrate B is the substrate of the enzyme.

[0022] The above kit can be used for enzyme-linked immunosorbent assay to detect the expression level of CTRB1 protein, specifically, it can be a double antibody sandwich method to determine the antigen. The enzyme-linked immunosorbent assay kit also includes a coating source, such as a CTRB1 protein antibody. In the kit used for the double antibody sandwich method, the coating source is a CTRB1 protein antibody, and the marker is an enzyme-labeled CTRB1 protein antibody or a biotin-labeled CTRB1 protein antibody.

[0023] The CTRB1 protein antibody is preferably a primary antibody, which can be a monoclonal antibody or a polyclonal antibody with the CTRB1 protein as an antigen. The CTRB1 protein antibody can be a mouse, horse, sheep, rabbit or guinea pig antibody, preferably a mouse antibody. When using the double sandwich method, two antibodies with different antigenic determinants or different species sources are required, wherein the coating source is preferably a mouse antibody.

[0024] The kit also includes a CTRB1 protein standard. The CTRB1 protein standard can be an enriched or expressed, synthesized human CTRB1 whole protein or a peptide segment containing a CTRB1 protein antigenic determinant.

[0025] The kit also includes concentrated sample diluent, antibody diluent, washing solution, color developing reagent, stop solution, etc. These reagents can be prepared by conventional methods.

[0026] Compared with the prior art, the present invention has discovered the upregulated protein CTRB1 in the serum of patients with gastric tumors through research, and provided a kit for detecting such protein as a basis for a kit for diagnosing gastric tumors, as well as a threshold standard for diagnosing gastric tumors using the kit, that is, a kit for diagnosing gastric tumors has been established using its characteristics, and the kit can be used for clinical detection of gastric tumors. The results show that the CTRB1 protein is significantly more highly expressed in the serum of patients with gastric tumors than in healthy people, so the kit for diagnosing gastric tumors by detecting the concentration of CTRB1 protein in the present invention has outstanding application value in clinical tests for diagnosing gastric tumors through peripheral blood. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 The results of CTRB1 protein content determination in the serum of healthy people and gastric cancer patients (mixed samples, No. 1-6 are gastric cancer patients, No. 7-15 are healthy people);

[0028] Figure 2 The results of ELISA detection of CTRB1 protein in serum samples of normal control group and gastric cancer patient group;

[0029] Figure 3 Figure 2 shows the ROC curve analysis results of CTRB1 protein level. DETAILED DESCRIPTION

[0030] The present invention is described in detail below in conjunction with the accompanying drawings and specific embodiments. This embodiment is implemented based on the technical solution of the present invention, and provides a detailed implementation method and specific operation process, but the protection scope of the present invention is not limited to the following embodiments.

[0031] The experimental methods used in the following embodiments are conventional methods unless otherwise specified; the reagents and biological materials used are commercially available unless otherwise specified.

[0032] The present invention found through experiments that the expression of CTRB1 protein in the serum of gastric tumor patients was upregulated, and further verified this conclusion through Western blot. The specific experimental method is as follows:

[0033] Western blot was performed to detect the CTRB1 protein level in the serum of the normal control group (healthy people) and the group of patients clinically identified as gastric cancer: first, the serum samples were subjected to conventional SDS-PAGE electrophoresis, transferred to a nitrocellulose membrane and placed in a blocking solution (5% skim milk in TBST) for 1 hour, incubated in a 1:1000 diluted CTRB1 protein primary antibody (Santa Cruz, sc-398721) at 4°C overnight, washed 5 times with TBST, added with a 1:1000 diluted goat anti-mouse secondary antibody (Thermo, 31430) and incubated at room temperature for 1 hour, washed 5 times with TBST buffer, and developed with an ECL kit (Yishen, 36208ES76).

[0034] The results are as follows Figure 1 As shown, it can be seen that the CTRB1 protein level is upregulated in the gastric cancer group. This result indicates that gastric tumors can be indicated by detecting the CTRB1 protein expression level.

[0035] Therefore, based on the above results, the present invention uses CTRB1 protein and / or its antibody to establish an ELISA detection kit for diagnosing gastric tumors by detecting the expression level of CTRB1 protein, which includes: a solid phase carrier, a marker, and a substrate that can react with the marker; the marker is an enzyme-labeled CTRB1 protein, an enzyme-labeled CTRB1 protein antibody, a biotin-labeled CTRB1 protein, or a biotin-labeled CTRB1 protein antibody. The specific kit can be composed of the following reagents: 1) an ELISA plate (solid phase carrier); 2) a human CTRB1 standard protein;

[0036] 3) marker; 4) sample diluent; 5) antibody diluent; 6) washing solution; 7) color developing reagent; 8) stop solution.

[0037] It is known to those skilled in the art that the above components are only schematic. The ELISA plate can be coated with a primary antibody (for double sandwich ELISA method, competitive method) or uncoated (for direct ELISA method). The human CTRB1 standard protein can be an enriched or expressed, synthesized whole protein or a peptide containing an antigenic determinant; the marker can be a horseradish peroxidase marker or a biotin marker; the color developing reagent can be TMB, OPD or ABTS, etc. The ELISA method can be a double sandwich method, a direct method or a competitive method. For ease of use, the kit can also include one or more of the following components: a negative control, a positive control, etc.

[0038] The method of using the kit is as follows:

[0039] 1) The ELISA plate was coated or not coated with CTRB1 antibody;

[0040] 2) Dilute the human CTRB1 standard protein to different concentrations with sample diluent, add it to the ELISA plate for incubation to prepare the standard curve, dilute the human serum sample to a certain concentration with sample diluent, add it to the ELISA plate for incubation for sample detection, and rinse with washing solution after incubation;

[0041] 3) The marker is diluted with diluent to a certain working solution, added to the ELISA plate for incubation, and then rinsed with washing solution;

[0042] 4) Add enzyme substrate for color development;

[0043] 5) Add stop solution to terminate the reaction;

[0044] 6) OD value determination and result calculation.

[0045] The reagents used are various reagents well known to those skilled in the art. For example, in step 1), the ELISA plate can be coated with CTRB1 antibody (double sandwich ELISA method) or not (direct ELISA method); the label used in step 3) can be labeled with horseradish peroxidase or biotin; the enzyme color substrate used in step 4) can be 3',3',5',5'-tetramethylbenzidine (3',3',5',5'-tetramethylbenzidine, TMB), o-phenylenediamine (O-phenylenediamine, OPD) or ABTS [2,2'-azino-di-(3-ethylbenziazobine sulfonate-6)], etc.; the wavelength used in step 6) corresponds to the color substrate used in step 4); the specific dilution concentration of the antibody, protein or sample in steps 1), 2) and 3) can be appropriately adjusted. CTRB1 antibody can use commercial products. The ELISA method can be a double sandwich method, a direct method or a competitive method.

[0046] The following specific examples are used to illustrate the principle of the present invention and verify the effect of the kit of the present invention.

[0047] Example:

[0048] The effectiveness of using an enzyme-linked immunosorbent assay kit for detecting CTRB1 protein expression levels as a kit for diagnosing gastric tumors was verified.

[0049] Composition of ELISA kit (double sandwich ELISA method):

[0050] The enzyme-linked immunosorbent assay kit for detecting CTRB1 protein used in this example (double sandwich ELISA method, Signalway Antibody (SAB) Company, Catalog No. EK13508, Human Chymotrypsinogen B1 (CTRB1) ELISA Kit) includes the following reagents:

[0051] 1) ELISA plate (solid phase carrier, coated with CTRB1 antibody);

[0052] 2) Human CTRB1 protein standard solution: concentration is 400 ng / ml, which is the full-length CTRB1 protein of GenBank No. X05006;

[0053] 3) HRP-labeled human CTRB1 antibody;

[0054] 4) Sample diluent;

[0055] 5) washing liquid;

[0056] 6) Colorimetric substrate reagent (the substrate is TMB);

[0057] 7) Stop solution.

[0058] The effect of the enzyme-linked immunosorbent assay kit for detecting CTRB1 protein in diagnosing gastric tumors is as follows:

[0059] The CTRB1 levels in serum samples from 17 normal control groups and 18 gastric cancer patients were detected by ELISA. The specific method is as follows:

[0060] 1. Take 100 μl of CTRB1 standard protein solutions of 0 ng / ml, 1.56 ng / ml, 3.12 ng / ml, 6.25 ng / ml, 12.5 ng / ml, 25 ng / ml, 50 ng / ml, 100 ng / ml and 400 ng / ml respectively and add them to the ELISA plate coated with the antibody. Make 3 parallel wells for each gradient to prepare the standard curve.

[0061] 2. Take 2 μl of serum samples from the normal control group (17 healthy people) and the gastric cancer patient group (18 patients) and dilute them with sample diluent (dilution multiple is 1:100). Take 100 μl of each sample and add it to the ELISA plate coated with the antibody. Make 3 parallel wells for each sample. The wells with only sample diluent added are used as negative controls.

[0062] 3. After the above samples were incubated at a constant temperature (37°C) for 2 hours, 300 μl of washing solution was added to each well and washed three times for 2 minutes each time.

[0063] 4. Add 100 μl of HRP-labeled human CTRB1 antibody to each well, incubate at 37°C for 1 hour, then add 300 μl of washing solution to each well and wash 4 times, 2 minutes each time.

[0064] 5. Add 90 μl / well of color substrate reagent and develop color at 37°C for 15 minutes; add 50 μl / well of stop solution and measure the OD value of each well sample at a wavelength of 450 nm.

[0065] 6. Draw a standard curve using the standard concentration and OD value, and calculate the CTRB1 protein content in each serum sample using the OD value measured in each well of the serum sample.

[0066] The results are as follows Figure 2 As shown, the results showed that the CTRB1 protein level was upregulated in patients with gastric tumors, with the average CTRB1 protein concentration in the normal control group being 6.22 μg / ml and that in the gastric cancer group being 16.68 μg / ml. Statistical analysis of the CTRB1 protein content in each group of samples revealed a significant difference in serum CTRB1 protein levels between the gastric cancer group and the normal control group.

[0067] 7. ROC curve analysis was performed on the serum CTRB1 protein level in the gastric cancer patient group.

[0068] The ROC curve analysis of serum CTRB1 protein level in gastric cancer group was performed by GraphPad Prism software, with the normal control group as the control group and the gastric cancer patient group as the disease group, AUC = 0.9420 (e.g. Figure 3 This indicates that the ELISA validation of the above human serum samples is highly reliable, indicating that CTRB1 is a potential marker that can be used for differential diagnosis of gastric tumor patients.

[0069] The above experimental results show that CTRB1 protein is significantly highly expressed in patients with gastric tumors. Therefore, the present invention uses an enzyme-linked immunosorbent assay kit for detecting the expression level of CTRB1 protein as a kit for diagnosing gastric tumors, or directly uses CTRB1 protein and / or CTRB1 protein antibodies to prepare a kit for diagnosing gastric tumors by detecting CTRB1 protein concentration, which has application value in clinical testing.

[0070] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.

Claims

1. Use of a kit for detecting the expression level of CTRB1 protein in serum in the preparation of a kit for diagnosing gastric tumors.

2. Use of a kit for detecting the expression level of CTRB1 protein in serum according to claim 1 in preparing a kit for diagnosing gastric tumors, characterized in that: The kit for detecting the expression level of CTRB1 protein is an enzyme-linked immunosorbent assay kit.

3. Use of a kit for detecting the expression level of CTRB1 protein in serum according to claim 1 in preparing a kit for diagnosing gastric tumors, characterized in that: The kit for detecting the expression level of CTRB1 protein in serum contains one or more of CTRB1 protein, CTRB1 protein antibody, CTRB1 protein marker, and CTRB1 protein antibody marker.

4. Use of a kit for detecting the expression level of CTRB1 protein in serum according to claim 3 in preparing a kit for diagnosing gastric tumors, characterized in that: The CTRB1 protein antibody is a monoclonal antibody or a polyclonal antibody. The monoclonal antibody is an antibody obtained by culturing a hybridoma cell line in vitro or an antibody obtained through commercial channels. The polyclonal antibody is an antibody obtained through commercial channels.

5. Use of a kit for detecting the expression level of CTRB1 protein in serum according to claim 3 in preparing a kit for diagnosing gastric tumors, characterized in that: The kit for detecting the expression level of CTRB1 protein is an enzyme-linked immunosorbent assay kit with the product number EK13508 produced by SignalAntibody, and the name of the kit is HumanChymotrypsinogen B1 (CTRB1) ELISA Kit.

Citation Information

Patent Citations

  • Non-coding transcripts for determination of cellular states

    US20130317083A1

  • Method for predicting and modulating susceptibility of cancer cell to programmed cell death

    US20200397817A1